151751-Najiba-Chargi

189 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 1 and table 2 show the differences in demographic, clinical, biochemical and anthropo - metric characteristic between patients who experienced cisplatin DLT and patients who did not experience cisplatin DLT. The SMM (LSMI) was significantly lower in patients with cisplatin DLT compared to patients without cisplatin DLT (LSMI 39.7 cm 2 /m 2 versus 42.4 cm 2 /m 2 ; p<0.01). Female patients were more likely to experience cisplatin DLT (n=60, 55.6%; p<0.01). No sig - nificant differences were seen in other demographic, clinical or biochemical characteristics. Interestingly, although cisplatin is currently dosed on body surface area, it was not significantly different between patients who experienced cisplatin DLT (1.9 m 2 ) and patients whomdid not experience cisplatin DLT (1.9 m 2 ) (p=0.2). However, LBM was significantly different between these patients (p<0.05). Patients who experienced cisplatin DLT had significant lower mean LBM (42.7 kg) compared to patients who did not experience cisplatin DLT (mean LBM 45.1 kg) (p=0.01). Patients who were underweight (n=30, 8.7%) were also more likely to experience cisplatin DLT (n=18, 60%; p=0.03). PREDICTORS FOR CISPLATIN DOSE-LIMITING TOXICITY Table 4 shows the univariate and multivariate logistic regression analysis of the predictors for cisplatin DLT. In univariate analysis, significant predictors for increased risk of cisplatin DLT were female gender (OR 1.88; 95% CI 1.18-2.97; p<0.01), LBM (OR 0.97; 95% CI 0.95-0.99; p=0.01) and low SMM at diagnosis (OR 1.20; 95% CI 1.20-2.89, p<0.01). Patients’ body surface area was not predictive for cisplatin DLT (HR 0.7, 95% CI 0.4-1.4; p=0.4). Subsequently, low SMM was included in the multivariate analysis with the clinically relevant variables, age at diagnosis and BMI. Female gender was not included in themultivariate analysis because 95.4% of patients with low SMM were female patients. The LBM was not included because LBM is calculated by use of SMA in the Mourtzakis formula, SMA is already represented in SMM. In multivariate analysis, low SMM at diagnosis (OR 1.75; 95% CI 1.06-2.90, p=0.03) remained the only significant predictive factor for cisplatin DLT. The Hosmer and LemesHow test showed that the multivariate analysis model had a high goodness-of-fit (Chi-square 8.11, p=0.42). 10